Introduction of sub-cutaneous infliximab (Remsima SC) expands treatment options for patients

Sponsored by Celltrion Healthcare Australia Pty Ltd

The recent TGA approval of subcutaneous (SC) infliximab (Remsima SC) across all current infliximab indications expands the treatment options for adult patients with chronic inflammatory diseases, including inflammatory bowel disease. The SC formulation was approved by the TGA in on 12th November 2020. The manufacturer, Celltrion, has applied for reimbursement, with hopes of PBS availability ...

Already a member?

Login to keep reading.

© 2021 the limbic